Quick Answer
ELITE PHARMACEUTICALS INC /NV/ reported Operating Income Loss of $19.60 million for the year ending 2025.
- ELITE PHARMACEUTICALS INC /NV/ showed an increase of +81.7% in Operating Income Loss from 2024 to 2025.
- This data is from ELITE PHARMACEUTICALS INC /NV/'s annual report (Form 10-K), filed with the SEC on June 30, 2025.
- XBRL data for this metric is available from 2011 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 15 years of available data (2011 to 2025), ELITE PHARMACEUTICALS INC /NV/'s Operating Income Loss has grown by 2,312.8%.
- Historical annual values: Fiscal year 2025: $19.60 million | Fiscal year 2024: $10.79 million | Fiscal year 2023: $3.68 million | Fiscal year 2022: $5.07 million | Fiscal year 2021: $2.10 million | Fiscal year 2020: -$2.29 million | Fiscal year 2019: -$9.16 million | Fiscal year 2018: -$9.05 million | Fiscal year 2017: -$7.36 million | Fiscal year 2016: -$8.32 million | Fiscal year 2015: -$16.51 million | Fiscal year 2014: -$5.28 million | Fiscal year 2013: -$1.56 million | Fiscal year 2012: -$1.97 million | Fiscal year 2011: -$885.8 thousand.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: